Supernus Pharmaceuticals
SUPN
213 hedge funds and large institutions have $685M invested in Supernus Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 83 increasing their positions, 82 reducing their positions, and 28 closing their positions.
140% more call options, than puts
Call options by funds: $3.77M | Put options by funds: $1.57M
21% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 28
13% more capital invested
Capital invested by funds: $604M → $685M (+$80.6M)
2% more funds holding
Funds holding: 209 → 213 (+4)
1% more repeat investments, than reductions
Existing positions increased: 83 | Existing positions reduced: 82
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$12.3M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$10.7M |
| 3 |
Bank of New York Mellon
New York
|
+$8.18M |
| 4 |
RIM
Ranger Investment Management
Dallas,
Texas
|
+$5.55M |
| 5 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$5.09M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kornitzer Capital Management
Shawnee Mission,
Kansas
|
-$6.06M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$5.67M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$5.35M |
| 4 |
MRM
Michael R. Murphy
|
-$4.95M |
| 5 |
State Street
Boston,
Massachusetts
|
-$4.79M |
SUPN Hedge Fund Activity: Q1 2016 in Review
213 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q1 2016, worth a combined $685M — up 13% from $604M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new SUPN positions and 28 closed out — a net gain of 6 holders — while 83 added to existing stakes and 82 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $12.3M. The largest seller was Kornitzer Capital Management, cutting an estimated $6.06M.
- 213 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q1 2016, up from 209 in Q4 2015.
- Funds reported $685M of Supernus Pharmaceuticals stock for Q1 2016, up 13% quarter-over-quarter.
- 34 funds opened new Supernus Pharmaceuticals positions in Q1 2016 and 28 closed out, a net change of +6 holders.
- The largest Supernus Pharmaceuticals buyer in Q1 2016 was Point72 Asset Management, an estimated $12.3M added.
- The largest Supernus Pharmaceuticals seller in Q1 2016 was Kornitzer Capital Management, an estimated $6.06M sold.
Based on aggregated 13F filings for Q1 2016.